@catchingupwithkels's postpartum GLP-1 claims, fact-checked
Quick answer
GLP-1 receptor agonists like semaglutide and liraglutide are FDA-approved medications that improve insulin sensitivity and promote weight loss through delayed gastric emptying and appetite suppression. The STEP 1 trial showed 14.9% weight loss with 2.4mg semaglutide over 68 weeks, but safety data for breastfeeding women remains limited.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this TikTok actually claim?
Kelsey's video tackles three supposed "lies" about GLP-1 receptor agonists for postpartum women. She claims these medications aren't just for weight loss but help with blood sugar, inflammation, and metabolic healing. She also suggests certain "natural activators" are safe while breastfeeding.
The video cuts off mid-sentence on the third "lie," but the overall message is clear: postpartum women are getting incomplete information about GLP-1 medications. She's positioning these drugs as metabolic healers rather than simple weight loss tools.
Is GLP-1 really about more than weight loss?
Yes, but let's get specific about what these drugs actually do. GLP-1 receptor agonists like semaglutide and liraglutide were originally developed for type 2 diabetes because they improve insulin sensitivity and reduce HbA1c by 0.8-1.5%.
The SUSTAIN-6 trial (Marso et al., NEJM, 2016) found semaglutide reduced cardiovascular events by 26% in diabetic patients. The STEP 1 trial (Wilding et al., NEJM, 2021) showed 14.9% weight loss with 2.4mg semaglutide over 68 weeks.
But here's where Kelsey gets fuzzy. There's no solid evidence these medications specifically help with "postpartum metabolic healing" or reduce systemic inflammation in new mothers. She's extrapolating from general metabolic benefits.
What about breastfeeding safety claims?
This is where things get problematic. Kelsey mentions "natural activators" that supposedly work safely during breastfeeding, but she doesn't specify what these are. If she's talking about actual GLP-1 medications like semaglutide or liraglutide, the data is limited.
The FDA hasn't approved these medications for breastfeeding women. A small study in Diabetes Care (2021) found minimal liraglutide transfer to breast milk, but we don't have long-term safety data for infants.
If she means supplements claiming to "activate" GLP-1 naturally, that's a different story entirely. These aren't regulated like prescription medications and their safety profiles during breastfeeding are even less established.
What's the real postpartum picture?
Postpartum women face genuine metabolic challenges. Insulin resistance can persist for months after delivery, and about 15-20% of women with gestational diabetes develop type 2 diabetes within 10 years according to CDC data.
But there's no specific research on GLP-1 receptor agonists for postpartum metabolic issues in healthy women. The studies we have focus on diabetic patients or people with obesity seeking weight management.
Kelsey's heart might be in the right place, but she's making medical claims without postpartum-specific evidence. New mothers dealing with metabolic concerns need individualized medical advice, not TikTok generalizations about "natural activators."
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @catchingupwithkels's postpartum GLP-1 claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@catchingupwithkels's postpartum GLP-1 claims, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonists like semaglutide and liraglutide are FDA-approved medications that improve insulin sensitivity and promote weight loss through delayed gastric emptying and appetite suppression.
FormBlends verdict
GLP-1 receptor agonists like semaglutide and liraglutide are FDA-approved medications that improve insulin sensitivity and promote weight loss through delayed gastric emptying and appetite suppression. The STEP 1 trial showed 14.9% weight loss with 2.4mg semaglutide over 68 weeks, but safety data for breastfeeding women remains limited.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide and liraglutide are FDA-approved medications that improve insulin sensitivity and promote weight loss through delayed gastric emptying and appetite suppression. The STEP 1 trial showed 14.9% weight loss with 2.4mg semaglutide over 68 weeks, but safety data for breastfeeding women remains limited.
- GLP-1 receptor agonists reduce HbA1c by 0.8-1.5% and showed 14.9% weight loss in the STEP 1 trial over 68 weeks
- These medications aren't FDA-approved for breastfeeding women due to limited safety data
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GLP-1 receptor agonists reduce HbA1c by 0.8-1.5% and showed 14.9% weight loss in the STEP 1 trial over 68 weeks
- These medications aren't FDA-approved for breastfeeding women due to limited safety data
- No specific research exists on GLP-1 drugs for postpartum metabolic healing in healthy women
- The SUSTAIN-6 trial found 26% reduction in cardiovascular events, but this was in diabetic patients, not postpartum women
- Claims about "natural GLP-1 activators" lack specificity and regulatory oversight
- About 15-20% of women with gestational diabetes develop type 2 diabetes within 10 years
- Postpartum metabolic concerns require individualized medical evaluation, not social media recommendations
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Kelsey | Toddler Mom Life · TikTok creator
393.3K views on this video
After having a baby, everyone tells you what you should do with your body — but rarely the full truth about GLP-1 support. Lie 1: “It’s only for losing baby weight.” Weight loss can happen, but GLP-1
Sources & references
- [1]Care (2021)
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Kelsey | Toddler Mom Life, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.